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Abstract 
MFN2 is a complicated gene diagnostically.  It has a large number of variants of uncertain 
pathogenicity and three described patterns of inheritance including dominant, semi-dominant and 
recessive which can cause difficulties for genetic counselling. We report a family in which two 
affected brothers both carried a p.R250Q and p.T362R mutation of MFN2 in trans. Both brothers 
developed an early onset, sensory motor neuropathy. The father, who is presumed to carry the 
p.R250Q mutation, died aged 63 and had no symptoms of a neuropathy. The mother who carries 
the p.T362R mutation has a very mild neuropathy. In both our case and that reported by 
Piscosquito and colleagues in this journal, these two variants appear to cause a late onset 
symptomatic axonal neuropathy in the heterozygous state but a more severe, early onset 
neuropathy in the compound heterozygous state. This raises the question as to whether clinicians 
should be offering routine diagnostic testing of the MFN2 gene to partners of patients with 
known mutations in MFN2 wishing to start a family.  
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Dear Editor,  
We read with interest the recent publication by Piscosquito and colleagues on mutational 
mechanisms in MFN2-related neuropathy in which they described a family where the proband 
had a severe axonal neuropathy with pyramidal signs due to a compound heterozygous mutation 
in MFN2 (Piscosquito, et al., 2015). One parent had a mild late onset axonal neuropathy due to a 
semi dominant p.R250W missense mutation and the other parent, carrying a single MFN2 null 
allele, was asymptomatic.  
MFN2 is a complicated gene diagnostically.  It has a large number of variants of uncertain 
pathogenicity and three described patterns of inheritance including dominant, semi-dominant and 
recessive which can cause difficulties for genetic counselling (Verhoeven, et al., 2006; Polke, et 
al., 2011; Nicholson, et al., 2008). We report a family in which two affected brothers both carried 
a c.749G>A, p.R250Q and c.1085C>G, p.T362R mutation of MFN2 in trans (See Table 1 for 
clinical details). Both brothers developed an early onset, sensory motor neuropathy. The father, 
who is presumed to carry the p.R250Q mutation, died aged 63 from a myocardial infarction and 
had no symptoms of a neuropathy. The mother who carries the p.T362R mutation has a very 
mild symptomatic neuropathy, diagnosed at the age of 85 with symptom onset of mild difficulty 
walking at age 70. She was unable to stand on her heels or toes, sensory action potentials were 
absent and compound muscle action potentials significantly reduced in the lower limbs. 
The elder brother presented in the first decade of life with difficulty running and poor balance. 
He underwent Achilles tendon lengthening surgery at the age of 10. He is now aged 53. He has 
length dependent weakness but with proximal involvement, requires a stick to walk and has 
unilateral vocal cord paralysis. Neurophysiology confirmed a length dependent sensory and 
motor neuropathy with both acute and chronic denervation on EMG in a length dependent 
pattern.  The younger brother is less severely affected. He developed muscle cramps in his 30s. 
By his late 40s he reported difficulty standing. Neurological examination revealed knee bobbing 
and significant ankle dorsiflexion and plantar flexion weakness. Neurophysiology confirmed a 
length dependent sensory and motor neuropathy. Brain MRI and ophthalmic examinations were 
not performed in any family members. 
The p.R250Q has been previously reported, however, the evidence for pathogenicity as a 
dominant mutation is not conclusive (Verhoeven, et al., 2006; McCorquodale, et al., 2011). In 
addition, it has been detected at a carrier frequency of 0.047% in European Americans by the 
NHLBI Exome Sequencing Project, and is listed on the ExAC database (exac.broadinstitute.org) 
at an allele frequency of 0.045% in non-Finnish Europeans. The p.T362R heterozygous variant 
has not been previously reported in the literature, though a different mutation affecting the same 
base p.T362M has been reported in an apparently unaffected carrier who was not examined 
(Polke, et al., 2011) and mildly affected individuals (Chung, et al., 2006; Nicholson, et al., 2008). 
Taken together this would suggest that both mutations may cause a very mild and often 
asymptomatic, late onset neuropathy in the heterozygous state (semi-dominant). 
With the advent of next generation sequencing into routine clinical practice, counselling patients 
on the significance of novel MFN2 variants has become even more complicated. In both our case 
and that reported by Piscosquito and colleagues, two novel variants appear to cause a late onset, 
mild axonal neuropathy but in the compound heterozygous state cause a more severe, early onset 
neuropathy. This raises the question as to whether clinicians should be offering diagnostic testing 
of the MFN2 gene to unaffected partners of patients with known mutations in MFN2 wishing to 
start a family. How to interpret the significance of any MFN2 variant in the unaffected partner is 
fraught with difficulty as many semi-dominant missense mutations, like those reported in this 
letter, are likely to be present on variant databases such as ExaC. Both our case and that reported 
by Piscosquito and colleagues highlight the need for a reliable functional assay to determine the 
pathogenicity of novel MFN2 variants. 
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Table 1. UL=Upper limbs; LL=Lower limbs; Prox=Proximal; ASIS=Anterior superior iliac 
spine, SAP=Sensory action potential; DTR=Deep tendon reflexes; CMAP=Compound muscular 
action potential; Amp=Amplitude; CV=Conduction velocity, ND = Not done; EDB=Extensor 
Digitorum Brevis; CMTSS=CMT symptom score; CMTES=CMT examination score; 
CMTNS=CMT neuropathy score 
  
 Patient  I.1 II.1 II.2 
Mutation  T362R R250Q/ 
T362R 
R250Q/ 
T362R 
Decade of 
onset 
 8th 4th 1st 
Age of 
evaluation 
 85 56 53 
Presenting 
Symptom 
 Poor balance Difficulty 
walking 
Difficulty 
walking 
 MRC score UL 
Prox/Distal 
 5/5 5/5 5/4 
MRC score LL 
Prox/Distal 
 5/4 5/3 4+/0 
DTR UL/LL UL Normal Normal Reduced 
 LL Absent Absent Absent 
Pin Prick UL Normal Normal Normal 
 LL Knee Ankle Knee 
Vibration  ASIS right 
Ankle left 
Normal Normal 
Optic atrophy  No No No 
CMT SS  5 3 7 
CMT ES  11 9 19 
CMT NS  11 9 23 
SAPs     
Radial Amp (µV) 18 16 4 
 CV (m/s) 55 61 64 
Median Amp (µV) 6 3 Absent 
 CV (m/s) 48 52 - 
Ulnar Amp (µV) Absent 1 Absent 
 CV (m/s) - 55 - 
Sural Amp (µV) Absent Absent Absent 
 CV (m/s) - - - 
CMAPs     
Median DML (ms) 3.8 3.6 4.0 
 Amp (mV) 4.8 8.0 2.6 
 CV (m/s) 53 50 52 
Ulnar DML (ms) 3 2.6 3.4 
 Amp (mV) 7.1 10.7 3.6 
 CV (m/s) ND 55 51 
Peroneal 
(EDB) 
DML (ms) 4.8 Absent Absent 
 Amp (mV) 0.1 - - 
 CV (m/s) 44 - - 
Table 1. 
